Tourette's syndrome: clinical features, pathophysiology, and therapeutic approaches. by Müller, Norbert
ourette's syndrome (TS) is a disease which has its
onset during childhood and/or adolescence and is often
life-long.Although the earliest descriptions of patients
with motor and vocal tics were passed down from the
ancient Greeks,Gilles de la Tourette was the first person
who systematically described nine cases of the disorder
that now bears his name,in 1885 when he was a student of
Charcot at the Salpétrière hospital in Paris.
Gilles de la Tourette reported a positive family history in
several of his nine original TS cases,rasing the question
of a genetic origin of the disorder.The etiology of TS,
however, was subsequently ascribed to psychogenic
causes until the 1950s.This perception began to change
in the 1960s,when the beneficial effects of neuroleptic
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Tourette's syndrome (TS) is a disorder characterized by simple and complex motor tics, vocal tics, and frequently obses-
sive-compulsive symptoms. Its onset occurs before the age of 21. Typically, TS shows a waxing and waning course,
but a chronification of the tics, even during later life, is often observed. TS mainly occurs in boys, and shows genetic
heritability with differing penetrance. The pathological mechanism is still unclear. Neuroanatomical and neuroimaging
studies, as well as effective treatment using antipsychotics, suggest that a disturbance of the dopaminergic system
in the basal ganglia plays an important role in the pathogenesis of TS. Several possibly causative mechanisms of the
disturbed dopaminergic neurotransmission are discussed, with the main emphasis on the—infection-triggered—
inflammatory immune process. Extrapyramidal movement disorders are known to occur as a symptom of poststrep-
tococcal disease, such as in Sydenham's chorea. Cases of childhood TS are proposed to be caused by such a post-
streptococcal mechanism, being part of a spectrum of childhood neurobehavioral disorders termed pediatric
autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS). The overlap between TS
and PANDAS is discussed, and a critical view of the PANDAS concept is presented. The therapeutic implications of the
different pathological mechanisms are described, taking into consideration not only the acute or chronic natures of
different infections, but also an autoimmune process. Moreover, therapeutic strategies using typical and atypical
antipsychotics, and also experimental therapies such as repetitive transcranial magnetic stimulation and deep brain
stimulation, are critically discussed.   
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This observation helped to refocus attention from psy-
chogenetic causes to Gilles de la Tourette’s view of bio-
logical central nervous system mechanisms.
In the following review,an overview of the advances made
in the understanding of TS,with a special focus on the role
of an infectious and inflammatory process,is provided.
Clinical and epidemiological features of TS
TS is clinically characterized by simple and/or complex
motor tics and simple or complex vocal tics (Tables I and
II),which cause marked distress or significant impairment
in social or other important areas of functioning
(Diagnostic and Statistical Manual of Mental Disorders.4th
ed [DSM-IV] criteria).
1 Sensory tics such as body sensa-
tions,eg,cold,heat,heaviness,urging,and touching,which
often preceed a motor tic,have been described in a large
number of TS patients.In sensory tics,the motor action
acts as a response to an internal or external stimulus.
2
A characteristic of TS is its great variability of symptoms.
Motor,vocal,and sensory tics start during childhood/ado-
lescence,and show a waxing and waning course,with exac-
erbations in periods of emotional stress;however,periods
without such obvious symptoms are also typical.
Symptoms other than tics such as echolalia and
echopraxia,palilalia,coprolalia,mutilations,and disturbed
impulse control characteristically often occur, although
they are not obligatory for the diagnosis of TS.
Furthermore,obsessions and compulsions,
3 cognitive dys-
function,or affective disturbances such as depression or
anxiety have frequently been described in these patients.
4,5
An increased comorbidity of TS and obsessive-compulsive
disorder (OCD),
3,6,7 mood disorders,and anxiety,
8,9 as well
as phobias
10,11 and attention deficit/hyperactivity disorder
(ADHD)
12,13 have been reported. Increased substance
abuse has been suggested,since the sedative effect of alco-
hol often improves the tics.
14 However,systematic studies
of substance abuse or dependency in TS are lacking.
Since the onset of TS is before the age of 18 (DSM-IV)
1
and often leads to severe psychosocial impairment,chil-
dren and adolescents suffering from TS are often dis-
criminated against and have disadvantages in terms of
psychosocial development.Moreover,the 50% to 60%
comorbidity with ADHD or OCD additionally con-
tributes to the impaired development of personality dur-
ing the critical period.Furthermore,these patients are
also more likely to experience academic as well as psy-
chosocial problems,and these conditions may contribute
to a chronification of the disorder on the one hand and
to the development of personality disorders on the other.
The prevalence of TS is estimated at about 4 to 5 per 10 000
according to the internationally accepted American esti-
mation of prevalence (DSM-IV).
1 Studies relying on stricter
methodological criteria describe a prevalence between 0.7
and 5.3 per 10 000.
15,16 Other findings suggest that,especially
in males,the prevalence is up to 1% of the population.
17
The male:female ratio for TS is around 4:1.
15
Delayed diagnosis of TS
The estimated time from onset of the first symptoms of
TS to the time the final diagnosis is established is about
5 to 10 years.
18 Since TS is characterized by severe socially
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Selected abbreviations and acronyms
ADHD attention deficit-hyperactivity disorder
OCD obsessive-compulsive disorder
PANDAS pediatric autoimmune neuropsychiatric disorder
associated with streptococcal infection
TS Tourette's syndrome
Table I. Examples of simple tics.
Simple motor tics Simple vocal tics
Blinking Throat-clearing
Turning the head Sniffing
Shrugging Coughing
Shaking of extremities Mumbling
Foot-stamping Flicking
Whistling
Grunting
Snoring
Barking
Table II. Examples of complex tics.
Complex motor tics Complex vocal tics
Touching Imitation of sounds
Lying down flat Repetition of senseless items
Deep knee bends Coprolalia
Pushups Echolalia
Steps backwards  Palilalia
Certain order of steps  Echokinesia
during walking
Turning arounddisabilitating symptoms,this delay causes additional neg-
ative reactions,and leads to significant psychosocial suf-
fering in many cases.Although controlled data are still
lacking,there are indications that the course of TS and
the patient's capacity to cope with it will be more favor-
able in cases where TS is diagnosed earlier. The high
comorbidity with emotional instability and personality
disorders may result at least partly from these problems.
TS: a syndrome of different etiologies and
variable phenomenology
Clinically,the symptoms of TS show a broad variability;
however,whether this variability corresponds to differ-
ences in the outcome as well as to the response to special
treatments has not been investigated.Furthermore,dif-
ferent etiological factors may contribute to TS.There is
no doubt that genetic factors which have not yet been
specified do play a pivotal role.Neurochemical and phar-
macological studies suggest a functional hypersensitivity
of dopaminergic neurotransmission and a dysfunction of
the opiatergic system.Probably,the disturbance of the
dopaminergic neurotransmission is the final stage of dif-
ferent pathogenetic pathways.Neurophysiological stud-
ies have shown reduced neuronal inhibition within the
sensorimotor loop, with good frontocortical compen-
satory mechanisms.
19Within a subgroup of TS patients,
recurrent or chronic inflammation may lead to a mani-
festation of tics. Recently, the diagnosis of postinflam-
matory immune processes after streptococcal infections
associated with tics or obsessive-compulsive (OC) symp-
toms,known as pediatric autoimmune neuropsychiatric
disorder associated with streptococcal infection (PAN-
DAS) has been established in the USA.Furthermore,TS
symptomatology can be the result of trauma,of intoxi-
cation, or of pharmacological treatment. There is evi-
dence that long-term treatment with classic neuroleptics,
as well as treatment of ADHD with stimulants, might
increase the risk of tic development in some children.
Differential diagnosis of TS
Due to the high variability of TS symptoms,the diagno-
sis of TS is often difficult.Since the typical course is one
of exacerbations and remissions,typical vocal or motor
tics often do not occur during the symptom-free intervals,
although these patients still suffer from other—often
comorbid—symptoms, hampering the TS diagnosis.
Mutilations, obsessive-compulsive (OC) symptoms, or
other behavioral “abnormalities” often dominate the
clinical symptoms.Moreover,patients suffering from TS
often describe their motor and vocal tics as compulsions.
3
Moreover,the suppression of tics for a certain time is a
diagnostic feature of TS,especially in situations where the
patient’s attention is drawn to them (eg,during a medical
examination).In particular,typical but awkward symp-
toms such as coprolalia, copropraxia, or echolalia, are
often concealed.
Regarding the differential diagnosis of TS (Table III),
other tic disorders such as chronic motor tic disorder,
which lacks vocal tics,must be excluded.In cases where
the disorder starts later than the consensus age of 18 or
21 years,even full-blown TS symptoms cannot be diag-
nosed as TS (DSM-IV).
1
Extrapyramidal movement disorders,but also OC symp-
toms,are known to occur as a symptom of poststrepto-
coccal disease,such as in Sydenham's chorea,for a long
time.
20,21 Huntington's disease,today easily diagnosed by
molecular genetic methods,is a movement disorder often
showing similar phenomena to TS;this differential diag-
nosis needs to be kept in mind. Pharmacologically
induced hyperkinesia,induced by,eg,L-dopa or amphet-
amine,is an important differential diagnosis,but tardive
dyskinesias,caused by antipsychotic therapy,often show
similar motor symptoms to tics.Moreover,schizophrenia
is often associated with movement abnormalities such as
stereotypic movements and motor automatisms,the lat-
ter also frequently found in organic brain disorders.This
has to be considered as well, particularly since schizo-
phrenia and TS have common pathogenetic features and
co-occur in certain cases.
22Apart from schizophrenia,psy-
chogenic movement disorders are an important psychi-
atric differential diagnosis in TS.
Neuroacanthocytosis is another group of neuropsychi-
atric disorders which shows features of TS.Primarily,it is
characterized by abnormal erythrocytes in the blood,
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Table III. Differential diagnosis of Tourette syndrome.
Pharmacologically induced hyperkinesias (L-dopa, amphetamine)
Huntington's disease
Sydenham's chorea
Metabolic disturbances (eg, Wilson's disease)
Schizophrenic stereotypes
Tardive dyskinesias
Motor automatisms
Psychogenic movement disordersacanthocythes,which seem to be the result of a heredi-
tary component and represent an impairment of struc-
tural proteins of the cellular membrane.The first symp-
tom of neuroacanthocytosis is often an epileptic seizure,
but OC symptoms, symptoms of ADHD, or tics are
described as manifestations of the condition.
23,24 In some
recent studies,in patients primarily presenting with tics,
genetic defects belonging to the group of neuroacantho-
cytosis syndromes,such as chorea-acanthocytosis,have
been reported.
25,26
TS is not only a movement disorder, 
but a psychiatric disorder
Because of its rich clinical expression and frequent asso-
ciation with comorbid disorders, the spectrum of TS is
often not recognized or fully appreciated.As our knowl-
edge about TS expands,however,it is becoming increas-
ingly obvious that TS is not merely a movement disor-
der,manifested by motor and vocal tics,but a relatively
common neurobehavioral complex manifested,in addi-
tion to tics, by attention deficit, OC symptoms, lack of
impulse control,and a variety of other behavioral symp-
toms. Since most cases of TS are mild and do not pro-
voke medical diagnosis and treatment,the patients seen
in the clinic represent only the tip of the iceberg.
Although no valid data exist regarding the frequency of
substance abuse, there is no doubt that many persons
suffering from TS show a comorbid substance abuse.
Alcohol and sedative drugs such as benzodiazepines
have a short-term effect on tics and other symptoms of
TS,leading to a high prevalence of alcohol abuse,which
is estimated at about 30% in our own sample(Muller,
unpublished observation).Due to the early onset of tics,
many children affected with tics are socially withdrawn;
they become outsiders in their families and peer groups.
This might promote the development of personality dis-
orders, which have been described in 60% of TS
patients.
27 A comorbid depressive syndrome is found in
about a quarter of affected persons.
11 Markedly higher is
the rate of comorbidity with ADHD, observed in 55%
of the TS patients.
28The comorbidity with OCD appears
to be even higher,having been described in 40% to 90%
of the patients.
5,29 However,due to the broad overlap of
tics, in particular complex tics and OC symptoms, there
is some discussion as to whether “specific”compulsions
such as symmetry behavior, echophenomena, or touch-
ing should be classified as tics or as OC behavior.
3,9
Neurobiological characteristics of TS
Although TS is a disorder of primarily the dopaminergic
system of the basal ganglia,there is no doubt that corti-
cal structures are also involved. The hypothesis of
Kurlan,
30 in particular,focuses on disinhibition within the
cortical-striatal-thalamic motor loop,including the lim-
bic system. Similar conclusions were drawn by studies
using transcranial magnetic stimulation, which show
reduced intracortical inhibition in TS patients.
31We found
that disturbed saccadic eye movements are in keeping
with the hypothesis of a disturbed activation of the
frontal cortex by ascending loops from the basal ganglia.
32
Moreover,the disturbed inhibition of unwanted orienta-
tion reactions revealed by antisaccades, as well as the
known attention problems,favor a functional impairment
of the frontal cortex in TS.
Brain morphology of TS
A neuroimaging study in adult TS patients without long-
term antipsychotic treatment revealed smaller mean vol-
umes of the caudate,lenticular,and globus pallidus nuclei
compared with controls, on both the right and left.
Further analyses of basal ganglia asymmetry indices sug-
gest that TS basal ganglia do not have the volumetric
asymmetry (left greater than right) seen in normal con-
trols.
33 Similar findings were reported by other
researchers studying a group of TS children: statistical
comparisons between TS patients,with (n=18) or with-
out (n=19) ADHD,and controls showed significant dif-
ferences in the volume of the left globus pallidus and in
lenticular asymmetry.
34 Interestingly,caudate volumes in
children with TS predict the severity of tic and OC symp-
toms in early adulthood.This study provides compelling
evidence that morphologic disturbances of the caudate
nucleus within cortico-striatal-thalamo-cortical circuits
are central to the persistence of both tics and OC symp-
toms into adulthood.
35These findings strongly support
the view that TS is related to a basal ganglia dysfunction,
although several other brain regions are involved in the
pathophysiology of tics as hypothesized by the concept
of Kurlan and shown by functional magnetic resonance
imaging (MRI).
36 Interestingly,neuroimaging data in TS
also show significantly increased white matter lesions in
the basal ganglia and other brain regions,a finding that
will be discussed in the context of the inflammatory
hypothesis of TS.
37
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There is evidence for a strong genetic background of TS.
It has been demonstrated in twin studies that monozy-
gotic twins are more often concordant for the presence
of TS in up to 53% or any tics in up to 77% compared
with dizygotic twins (up to 8% concordant for TS and
23% for any tics).
13,14While it is evident that genetic fac-
tors play a profound role,the phenotype may be variable
and may not be confined to full-blown TS.
The risk for TS is sex-dependent:11.5% for brothers of
an affected person and 4.8% for sisters.
38The frequency
of TS in first-degree relatives ranges from 9.8% to 15%,
according to the study cited.
39,40
A particular risk gene for TS,however,has not yet been
identified.Although large linkage studies have been per-
formed, a genome-wide screen for linkage using 386
markers did not show a limit of detection (LOD) score
of more than two,
41 nor did a genome-wide screen based
on 110 sib pairs,show significant loci.
42A sample from a
French-Canadian family (127 members,20 to 40 affected)
showed a LOD score greater than three on 11q23.
43
However, the incomplete genetic penetrance, the high
variability of the phenotype (symptoms),possible differ-
ent etiological factors,and several other concomitant fac-
tors complicate genetic studies in TS.
TS as an inflammatory disease
Recent studies suggest that an inflammatory process,due
to an acute or chronic infection or a postinfectious immune
response,may be involved in the pathogenesis of TS.
44
Although the pathological mechanism in TS is unclear,
contribution of an immunological dysfunction or an
inflammatory process has been discussed.With regard to
research on immune function in TS, most studies have
focused on antibody production.Increased antibody pro-
duction including antiphospholipid
45 and antineural anti-
bodies directed against structures in the basal ganglia
46-50
has been described. Recent research, however, showed
conflicting results regarding increased antineural anti-
bodies in the serum of TS.
51-53 D8/17,a surface marker on
antibodies producing B-lymphocytes,has been described
to be a diagnostic marker in OCD and in tics,
54 but this has
not been confirmed.
55 However, increased titers of
antiphospholipid antibodies,and increased IgE levels have
been described in TS.
45,56,57 In recent years,immunological
research in TS has focused on cytokines. In a recent
prospective longitudinal study,increased serum levels of
the cytokines interleukin (IL)-12 and tumor necrosis fac-
tor (TNF)-α in juvenile TS patients were observed.
58
During exacerbations of tics,a further increase in IL-12
and TNF-α was observed, pointing to a relationship
between tic severity and proinflammatory cytokines.In
OCD, however, decreased levels of TNF-α were
described.
59-61 Since OCD and TS show a high rate of
comorbidity,a possibly discriminative marker—decreased
in OCD and increased in TS—would be very valuable.
Although the results of the kynurenine estimations in TS
are divergent,depending on interfering factors,
62,63 changes
in the kynurenine levels in the sera of TS patients also
point to the involvement of the immune system.
Kynurenine is the product of activated monocytes/
macrophages; changes in kynurenine production take
place during inflammatory processes.Moreover,kynure-
nine and other products of the tryptophan/kynurenine-
metabolism are neuroactive proteins,possibly themselves
contributing to changes in neurotransmitter metabolism.
Moreover,increased levels of the soluble adhesion mole-
cules V-CAM-1 and E-selectin—increased in inflamma-
tory states—were reported in children and adults suffer-
ing from TS.
64
A case report of successful treatment with a cyclo-oxy-
genase (COX)-2 inhibitor also promotes the view that an
inflammatory process is involved in TS.
65
Inflammation in TS as a result of 
an infectious or postinfectious process
It has been described that tics appear or are exacerbated
in acute Lyme disease,
66 infection with Mycoplasma pneu-
moniae,
67,68 or acute streptococcal infection.
69 Moreover,
an association of the common cold with tic disorders has
been observed.
63 Improvement or remission of the tics
has been associated with antibiotic therapy.
65,66,68 These
findings strongly suggest that infectious agents contribute
to the pathogenesis of tics and TS.
PANDAS
70,71 has been extensively described during
recent years.The main symptoms of PANDAS are motor
and vocal tics and OC behavior like that found in TS.
72
Although crossreacting antibodies against the putamen
have been observed in PANDAS,
73 the mechanism has
not yet been established.TS is proposed to be a part of
PANDAS.Increased antibody titers and other features
of PANDAS,however,have also been described in adult
TS patients,
74,75 while the PANDAS concept is restricted
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proteins,ie,proteins on the surface of streptococci which
are known to be responsible for the virulence and the
immune properties of the particular streptococcal strain,
are increased in children and adult TS patients.In par-
ticular, antibodies against M12 and M19, which are
known to crossreact with brain cells, are increased in
these patients,while no difference could be detected in
other, more frequent M-protein antibody titers.
76 This
finding—in addition to others with cross-reacting anti-
bodies—shows that a poststreptococcal autoimmune
process is involved in TS.This is the basis for the suc-
cessful application of immune-modulating therapeutic
approaches in TS and PANDAS.
72
Different types of infectious agents and different stages
of infection—eg,acute streptococcal infection
77 and post-
streptococcal inflammation,
75 were reported to be asso-
ciated with TS.The therapy, however, has to take into
consideration different therapeutic strategies for acute
or chronic infection,or for a postinfectious autoimmune
process.Therefore—although there are continuous tran-
sitions between these inflammatory states—research
should focus on the differentiation and differential ther-
apies of these stages of inflammation.
Anti-inflammatory therapy in TS, eg, use of a COX-2
inhibitor,has also shown positive effects.
65Altogether,the
involvement of inflammatory immunological mechanisms
in the pathogenesis of TS,at least in a subgroup of patients,
is obvious.A multifactorial pathogenesis has been pro-
posed,with the involvement of an (immuno)genetic pre-
disposition and environmental factors such as infection or
postinfectious phenomena.Further research also has to
identify markers for the differentiation of inflammation-
mediated and other forms of TS.
Recent findings from T2-weighted MRI in patients with
TS,but also other syndromes (OCD and ADHD,which
show a high prevalence of comorbidity with TS) revealed
a significantly higher frequency of cortical and subcorti-
cal hyperintensities compared with controls, a finding
which is in accordance with an inflammatory process in
certain cases of TS.
37
Shortcomings of the PANDAS concept
The PANDAS concept, however, is limited by several
shortcomings.Although this disorder is associated with
streptococcal infection, no test for streptococci to sup-
port the infection, is required for the diagnosis. An
objective parameter supporting the clinical diagnosis
(eg, increased antistreptococcal titers) would help to
confirm the diagnosis.
Moreover, different stages of streptococcal infection
might lead to different therapeutic consequences.
Although acute and chronic infection with streptococci
require antibiotic treatment,a poststreptococcal autoim-
mune process may respond better to immunomodulatory
therapy.A further difficulty for the PANDAS diagnosis
might be the heterogeneity of the symptoms, which
include not only motor and vocal tics,but also OC symp-
toms, which often, but not necessarily, co-occur in one
child.The restriction of the PANDAS concept to chil-
dren/adolescents,however,is a further point for discus-
sion.Tics and OC symptoms also often occur in adults.
Accordingly,an association between tics and infectious
agents in adults has been reported.
67,78 Although it is
known that children and adolescents are more vulnera-
ble to certain infections,the association between tics,OC
symptoms,and infection is not restricted to this popula-
tion.Moreover,studies have shown that not only strep-
tococci but also other infectious agents such as Borellia
Burgdorferi or Mycoplasma Pneumoniae are associated
with tics,ie,the association of tics and infectious agents
is not restricted to streptococci.A broader concept of this
association,however,would more fulfill the needs for an
infectious concept of TS.
Conventional pharmacotherapeutic 
concepts of TS
There is no doubt that dopaminergic neurotransmission
is involved in the pathophysiology of TS.Dopamine (D2)
receptor blocking agents such as haloperidol or pimozide
have been shown to be effective in TS in several studies.
79
Haloperidol showed an efficacy between 78% and 91%
in 41 reports over a 14-year period.
4 Many patients,how-
ever,discontinue haloperidol due to extrapyramidal side
effects,while pimozide showed a superior profile regard-
ing side effects.Pimozide was effective in several double-
blind,placebo-controlled studies.
80There are also reports
of effective treatment with drugs such as fluphenazine,
penfluridol,trifluoperazine,and flupenthixol.
81
In the meantime,atypical antipsychotics such as risperi-
done,which is not only a D2 receptor antagonist,but also
a serotonin (5-HT)2 antagonist, has been shown to be
effective in TS.
82,83 Clozapine was observed to be effective
against tics,
84 although there have also been negative
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results reported.
81A partial control of tics during therapy
with olanzapine at a dose of 5 to 10 mg/day was reported,
as well as a reduction in tics in a controlled study (n=4).
85
Ziprasidone,at a dose of 5 to 40 mg/day,was shown to be
significantly more effective than placebo in 28 patients
(7 to 17 years old) in a double-blind,randomized study,
and was well tolerated.
86 It should be noted, however,
that the sudden death of a TS patient under therapy with
ziprasidone during a clinical trial was reported.
87
Aripiprazole,a new atypical antipsychotic that acts as a
dopaminergic modulator showing mixed dopamine
antagonistic and agonistic effects, may take a special
position in the therapy of TS.Effective treatment of TS
using aripiprazole was reported repeatedly,in contrast to
those treated with other antipsychotics, a number of
patients showed complete recovery from tics without sig-
nificant adverse effects.
88-90
The drug of first choice,for therapy of tics,particularly
for children in many European countries,is tiapride,a
benzamide derivate,which selectively blocks dopamine
in the basal ganglia. Although only double-blind,
placebo-controlled studies show beneficial effects on
movement disorders and tics,
91,92 tiapride is widely used
in countries such as Germany, France, and others. It is
one of the few drugs which is prescribed not only in
adults,but also in children.In contrast to several antipsy-
chotics,however,no adverse effects on cognitive perfor-
mance in children have been observed.
92
However,clonidine,a central α2-adrenoceptor agonist
reducing noradrenergic activity in the central nervous
system, has also been reported to be effective in TS,
although controversial effects of clonidine in different
studies were shown in a dose of 3 to 5 µg/kg body
weight.
93,34 Possibly,the beneficial effects of clonidine on
behavioral abnormalities are more pronounced than on
vocal and motor tics.In general,antipsychotics seem to
be more effective compared with clonidine.
95The effect
of clonidine,however,shows that noradrenergic neuro-
transmission is also involved in TS.
Furthermore,the differentiation and characterization of
subgroups may lead to different therapeutic strategies,
for example,early antibiotic treatment in cases in which
tics are the result of infection may help to prevent pro-
gression to chronic stages which otherwise have to be
treated with neuroleptics.Therapy with immunoglobulin
IV and plasmapheresis as immunomodulatory treatment
strategies are currently the objective of therapeutic tri-
als.
72 Treatment with cannabinoids, in particular 19-
tetrahydrocannabinol,has shown beneficial effects in sin-
gle cases,but a randomized,double-blind study failed to
show convincing effects.
96
Behavior therapy
Until the introduction of haloperidol,TS was thought to
be a psychogenic syndrome;psychoanalytic therapeutic
concepts were very common and widely practiced.This
concept totally changed during recent decades.However,
supportive psychotherapy and training in coping strate-
gies,supported by concepts of self-help care,are known
to be very important,in particular in such a chronic and
socially isolating disease.Although tics and other symp-
toms can not be influenced decisively,behavior-therapy
techniques,including progressive muscle relaxation as
well as learning and training of alternative behavior,can
reduce the tic intensity and frequency.This technique of
habit reversal is based on the identification of tic-pre-
ceding sensations (premonitory urges).
97
Experimental therapeutic approaches in TS
Immunomodulatory and anti-inflammatory therapies
For children with PANDAS, effective treatment with
immunomodulatory substances or techniques have been
described repeatedly.
72 These therapies include IV
immunoglobulin G (IgG) and plasmapheresis,the latter
showing even better results than IV IgG.Keeping in mind
the critical view of PANDAS,these immunomodulatory
therapies might also reveal favorable effects in TS
patients not fulfilling PANDAS criteria.Effective IV IgG
therapy has been described in TS.
98
In the case of an acute or possibly also a chronic infec-
tion associated with tics, the TS symptoms including
motor and vocal tics are cured by antibiotics.This has
been reported for infection with Lyme-Borreliosis,
66
Mycoplasma Pneumoniae,
99 and streptococci.
69,77
In a retrospective,open-label study in 34 TS patients,the
effects and predicting variables for therapeutic effects of
IV IgG versus antibiotics were evaluated.It was observed
that increased antistreptococcal titer of antiDNase pre-
dicted better effects of antibiotics, and increased anti-
chlamydial titers better effects of IV IgG.Around 60% of
the total sample showed a therapeutic response to either
immunomodulatory treatment.
100 These interesting, but
very preliminary,results require further controlled studies.Clinical research
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Moreover,anti-inflammatory treatment with the COX-2
inhibitor celecoxib was described to be effective in TS in
a single case,
65 a result also requiring further examination.
Repetitive trancranial magnetic stimulation
A small, open-label study using repetitive trancranial
magnetic stimulation (rTMS) over the supplementary
motor area of 10 TS patients showed clinically significant
improvement of TS and accompanying OCD symptoms,
with benefits lasting up to 3 months in almost two thirds
of the patients.
101 Other studies,however,failed to bring
about improvement using another application of rTMS,
102
while in a crossover trial using high-frequency stimula-
tion of the left prefrontal cortex,a significant improve-
ment of the tics was observed.
103At this stage of knowl-
edge,further studies have to be performed in order to
optimize the localization,the technique,and the number
of rTMS-applications, and the sustainability of the
effects. RTMS seems a promising method, although it
requires elaborate and costly equipment, because it
shows only marginal side effects.
Electroconvulsive therapy
Single case reports describe therapeutic effects of electro-
convulsive therapy (ECT) on motor tics,vocal tics,and OC
behavior.
104,105 Maintenance ECT therapy (one treatment
every 4 to 6 weeks) was reported to be effective in a ther-
apy-resistant case of TS.
106Those reports reveal that ECT
is a therapeutic option in treatment-resistant cases of TS.
Deep brain stimulation
During recent years, surgical deep brain stimulation,
known to be effective in Parkinson’s disease and certain
dystonic syndromes,has been increasingly performed in
treatment-resistant cases of TS.Stimulation electrodes
were placed in various locations.Bilateral stimulation of
the thalamus showed moderate improvement of the tics
in five cases.
107,108 Bilateral stimulation of the globus pal-
lidus internus showed good and very good results in two
cases,
109,110 while bilateral stimulation of the nucleus
accumbens revealed moderate improvement of tics and
OC symptoms.
111,112
Conclusion
Although important progress in our knowledge about TS
has been made during the last few decades, this syn-
drome is still poorly understood.The pathophysiology is
unknown,but therapeutic strategies are more and more
successful.During recent years,the role of inflammation,
due to infection associated with a dysfunction of the
immune system,has come more into the focus of inter-
est. In addition to a broad spectrum of promising new
experimental therapeutic approaches, future research
will put emphasis on the role of inflammation,on the dif-
ferentiation and differential therapies of these stages of
inflammation,and on the identification of markers for
the differentiation of inflammation-mediated and other
forms of TS,because TS is a syndrome of different eti-
ologies and variable phenomenology. ❏
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Síndrome de la Tourette: características 
clínicas, fisiopatología y aproximaciones
terapéuticas
El síndrome de la Tourette (ST) es un trastorno
caracterizado por tics motores simples y complejos,
tics vocales y frecuentemente síntomas obsesivo-
compulsivos. Se presenta antes de los 21 años.
Típicamente el ST muestra un curso con fluctuacio-
nes, pero con frecuencia se observa una cronifica-
ción de los tics, aun durante las últimas etapas de
la vida. El ST se presenta de preferencia en niños
varones y muestra una herencia genética con pene-
trancia variable. El mecanismo patológico aun no
está aclarado. Los estudios neuroanatómicos y de
neuroimágenes, al igual que el tratamiento efec-
tivo con neurolépticos sugiere que una alteración
del sistema dopaminérgico en los ganglios basales
tiene un papel importante en su patogénesis. Se
discuten algunos posibles mecanismos causales del
trastorno de la neurotransmisión dopaminérgica,
con un principal énfasis en el proceso inflamatorio
inmune gatillado por la infección. Se sabe que los
trastornos de los movimientos extrapiramidales
ocurren como síntoma de enfermedades estrepto-
cócicas, como en el corea de Sydenham. Se ha pro-
puesto que algunos casos de ST en la niñez sean
causados por tal mecanismo postestreptocócico,
siendo parte del espectro de trastornos neurocon-
ductuales de la niñez llamado PANDAS (trastorno
neuropsiquiátrico pediátrico autoinmune asociado
con enfermedad estreptocócica). Se discute la
sobreposición entre ST y PANDAS y se presenta una
visión crítica del concepto de PANDAS. Se describen
las repercusiones terapéuticas de los diferentes
mecanismos patológicos, tomando en consideración
no sólo la naturaleza aguda o crónica de las dife-
rentes infecciones, sino también un proceso autoin-
mune. Además se discuten críticamente las estrate-
gias terapéuticas que utilizan antipsicóticos típicos
y atípicos como también terapias experimentales
como la estimulación magnética transcraneal repe-
titiva y la estimulación cerebral profunda. 
Syndrome de Gilles de la Tourette : 
tableau clinique, physiopathologie et 
approches thérapeutiques
Le syndrome de Gilles de la Tourette (SGT) est une
maladie caractérisée par des tics moteurs simples et
complexes et par des symptômes obsessionnels-
compulsifs fréquents. Il débute avant l’âge de 21
ans. Le SGT suit habituellement une évolution crois-
sante puis décroissante, mais une chronicisation des
tics, même à l’âge adulte, est fréquente. Le SGT se
rencontre principalement chez les garçons, avec
une héritabilité génétique à pénétrance variable.
Le mécanisme pathologique reste encore obscur.
Les études de neuroanatomie et de neuro-image-
rie, ainsi que l’efficacité des traitements utilisant
des antipsychotiques, suggèrent qu’un trouble du
système dopaminergique dans les ganglions de la
base joue un rôle important dans la pathogénie du
SGT. Plusieurs mécanismes éventuellement respon-
sables de la perturbation de la neurotransmission
dopaminergique sont envisagés, le principal étant
un processus immunitaire inflammatoire activé par
l’infection. On sait depuis longtemps que des mou-
vements anormaux extrapyramidaux se présentent
comme des symptômes de maladie post-strepto-
coccique, comme dans la chorée de Sydenham.
Certains cas de SGT juvéniles seraient peut-être pro-
voqués par un tel mécanisme post-streptococcique,
appartenant à l’éventail des troubles neurocom-
portementaux de l’enfance appelé trouble neuro-
psychiatrique auto-immun pédiatrique associé à
une infection streptococcique (PANDAS). Le che-
vauchement entre le SGT et le PANDAS est débattu
et le concept de PANDAS est présenté dans l’article.
Les implications thérapeutiques des différents
mécanismes pathologiques sont décrites en prenant
en compte non seulement la nature aiguë ou chro-
nique des différentes infections, mais aussi l’exis-
tence d’un processus auto-immun. Les stratégies
thérapeutiques utilisant des antipsychotiques
typiques et atypiques ainsi que les traitements
expérimentaux tels que la stimulation magnétique
transcrânienne répétitive et la stimulation cérébrale
profonde, sont de plus revus de manière critique. Clinical research
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